AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03570957
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution for injection in vial
Trial: NCT02555449
Drug: [¹⁴C]-LY3202626
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as solution by mouth
Trial: NCT03573999
Drug: NaCl 7.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml/kg will be administered before dura opening
Trial: NCT01118377
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine was supplied as film-coated tablets.
Trial: NCT00268918
Drug: PTK787
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants may continue receiving study drug as long as their disease does not worsen
Trial: NCT03181464
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline .9% injection
Trial: NCT02348125
Drug: Mitochondrial Cocktail
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00575523
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1ml 0,9% Saline solution is administered intravenously immediately before starting percutaneous ethanol instillation.
Trial: NCT01462058
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, daily, 12 weeks
Trial: NCT01771978
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Received 250 ml of a 5% dextrose solution as placebo
Trial: NCT04039126
Drug: CHEMICAL PLEURODESIS WITH POVIDONE-IODINE-TETRACYCLINE COMBINATION
RxNorm normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pleurodesis is the obliteration of the pleural cavity by inducing adhesions of the visceral and parietal pleural layers, mostly used in patients with pleural effusions, pneumothorax (18). The use of pleurodesis to induce pleural symphysis between the pleural layers dates backs to the beginning of the 20th century by Benthune(19) and has continued to evolve with different Thoracic surgeons and researchers still looking for the ideal pleurodesis agent.
Trial: NCT00502671
Drug: capecitabine [Xeloda]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1250mg/m2 po bid on days 1-14 of each 3 week cycle
Trial: NCT01179581
Drug: GLPG0634
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single ascending doses, oral solution (1 to 10 mg/dose) and capsules (10 to 200 mg/dose)
Trial: NCT01179581
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose, oral solution or capsule (matching corresponding study medication)
Trial: NCT01179581
Drug: GLPG0634
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple dose, capsule, 10 days
Trial: NCT01179581
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple dose, capsule, 10 days
Trial: NCT03633344
Drug: Carbowhite
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03633344
Drug: Carbowhite placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03071068
Drug: Anti-PlGF recombinant monoclonal antibody, 4mg dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 intravitreal injections of THR-317 4mg approximately 1 month apart
Trial: NCT03071068
Drug: Anti-PlGF recombinant monoclonal antibody, 8mg dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 intravitreal injections of THR-317 8mg approximately 1 month apart
Trial: NCT00092014
Drug: Risendronate placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risendronate placebo was taken once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.
Trial: NCT01919944
Drug: VLY-686
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules containing either 10 mg or 50 mg VLY-686
Trial: NCT01919944
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar capsule to mimic either VLY-686 10 mg capsule or 50 mg capsule
Trial: NCT02042521
Drug: Dietary Supplement
RxNorm normalized name: dietary supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The active evening dietary supplement is taken at 22:00. The active morning dietary supplement is taken at 8:00-8:15. The active evening dietary supplement is taken first. The active morning and evening dietary supplements are taken within 12 hours in time points as specified above.
Trial: NCT02042521
Drug: Lactose Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This research study involves a placebo dietary supplement that does not have any of or only partial of the active ingredients in the active dietary supplement. The placebo dietary supplement will be given in identical time points to match that of the active dietary supplements.
Trial: NCT00669214
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients received a conditioning dose of placebo equivalent SC on Day 0, followed by 11 weekly doses of placebo SC beginning on Day 7. After 12 weeks of blinded treatment, all patients continued into the open-label efalizumab treatment period from Day 84 (Week 12) through Day 168 (Week 24).
Trial: NCT00092014
Drug: Alendronate placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate placebo was taken once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.
Trial: NCT02327728
Drug: Botulinum toxin A 12.5U
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00717951
Drug: docetaxol, cisplatin, capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: docetaxol(75mg/m2 d1 every 21 days) combined with cisplatin(75mg/m2 d1 every 21 days) VS docetaxol( 75mg/m2 d1 every 21 days) combined with capecitabine(2000mg/m2 d1-14 every 21 days)
Trial: NCT04441112
Drug: Ketorolac Intraarticular Injection
RxNorm normalized name: ketorolac Injection
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injections will be given under ultrasound guidance with one of two possible medications.
Trial: NCT01227980
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg, orally, once/day during week 1, 100 mg, orally, once/day during weeks 2 and 3.
Trial: NCT03903081
Drug: HEC110114 tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered orally once daily
Trial: NCT03903081
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered orally at a dose and frequency matched to HEC110114
Trial: NCT01573598
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo given orally, once per day
Trial: NCT02398240
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Days: 1 and 15 Dose: 25 mg/m2/dose.
Trial: NCT04275193
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granule manufactured to mimic Zishenqing(containing 10% composition)
Trial: NCT00486759
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to bevacizumab was administered on Day 1 of each 14- or 21-day cycle for 8 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
Trial: NCT02174328
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid once a day until 36 week
Trial: NCT02174328
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once a day until 36 week
Trial: NCT02868151
Drug: Ascorbic Acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid oral supplementation 1g four times daily for the entire treatment period and 30 days after treatment by tapering the dose of the drug to half. The drug has to be started 2 days prior to initiation of treatment of cancer.
Trial: NCT02868151
Drug: Zinc acetate
RxNorm normalized name: Zinc Acetate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc acetate 50mg tablets orally twice daily for entire period of cancer treatment
Trial: NCT02631148
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2mg controlled release melatonin tablet
Trial: NCT02631148
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablet identical to circadin
Trial: NCT03647657
Drug: Sacuitril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication with Sacuitril (100 mg Entresto) additional to the injection of 177Lu-PP-F11N
Trial: NCT00997919
Drug: MABT5102A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single SC dose
Trial: NCT00997919
Drug: MABT5102A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single IV dose
Trial: NCT02926989
Drug: Plasmalyte Glucos 50 mg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution contains potassium chloride 5 mmol/L and sodium chloride 140 mmol/L.
Trial: NCT02926989
Drug: 0.45% saline in 5% dextrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution contains potassium chloride 20 mmol/L and sodium chloride 80 mmol/L.
Trial: NCT00726648
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsules for 4 weeks
Trial: NCT01613677
Drug: BKM120
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01372969
Drug: Cx601
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension of adult expanded allogenic adipose-derived stem cells (eASCs) at a doses of 20 million cells and 40 million cells.
Trial: NCT02405156
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04486651
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as IV infusion on Day 1 of each 21-day cycle.
Trial: NCT02635607
Drug: rhCG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An amount of 250ug rhCG will be administered to induce final oocyte maturation as soon as at least three follicles of ≥17 mm were observed
Trial: NCT03564652
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A single prophylaxis dose of 20 mg/kg in suspension form, reconstituted by trial staff before dose administration by the same.
Trial: NCT01134562
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single IV injection.
Trial: NCT01060137
Drug: fentanyl matrix
RxNorm normalized name: FentaNYL Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl transdermal patch 12 - 25mcg/hr
Trial: NCT02525796
Drug: eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: eplerenone, titrated up to a maximum of 50mg BID
Trial: NCT02525796
Drug: amiloride
RxNorm normalized name: Amiloride
DrugBank: Amiloride (DB00594)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: amiloride, titrated up to a maximum of 10mg BID
Trial: NCT03656094
Drug: Placebo plus chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus chemotherapy
Trial: NCT02338245
Drug: ASLAN001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASLAN001 400mg BID
Trial: NCT02338245
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1000mg/kg BID days 1-14 of a 21-day cycle
Trial: NCT01745367
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04675944
Drug: BIA 5-1058
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg (2 x 100 mg tablets), oral route
Trial: NCT01498497
Drug: EUR-1100
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01498497
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02890368
Drug: TTI-621 + PD-1/PD-L1 Inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TTI-621 will be given in combination with one of the following programmed death-1 (PD-1) or programmed death-ligand-1 (PD-L1) inhibitors: nivolumab, pembrolizumab, durvalumab, avelumab, or atezolizumab administered on Day 1. Subjects in this cohort must have a cancer diagnosis for which a PD-1/PD-L1 inhibitor is approved by the FDA or listed in the National Comprehensive Cancer Network (NCCN) Guidelines.
Trial: NCT02536430
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: buccal infiltration of Normal Saline.
Trial: NCT01241435
Drug: LY2216684
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01128530
Drug: JNJ-32729463 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 placebo tablet twice daily
Trial: NCT01586299
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 mg/kg every 8 hours until 24 hours after resolution of fever
Trial: NCT01586299
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/kg every 6 hours until 24 hours after resolution of fever
Trial: NCT00765934
Drug: Rapydan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lidocaine / tetracaine 70/70 mg patch
Trial: NCT01284517
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Equivalent to Lurasidone dosing
Trial: NCT04140396
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline infusion at 10mL/hour
Trial: NCT03583112
Drug: Placebo Tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral one placebo tablet before MRI scan.
Trial: NCT02339441
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Immunosuppressant agent. Patients treated with Methotrexate at the entry of the study, either oral or subcutaneous with a target dose of 20-25mg weekly.
Trial: NCT03354039
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomised to placebo will be administered matching placebo. Treatment will be given for the total period of 48 weeks.
Trial: NCT02339441
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Immunosuppressant agent. Patients treated with Methotrexate at the entry of the study, recommend use (i) IV. Minimum monthly dose 500mg/m2 with a recommended duration of 6-12 months. (ii) Oral. 1-2mg/day with a recommended duration of 12 months.
Trial: NCT03117816
Drug: AOP2014 / Pegylated-Proline-interferon alpha-2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AOP2014 as pre-filled auto-injection pen for subcutaneous injection, containing 250 µg AOP2014 / 0.5 ml. The solution also contains inactive ingredients (sodium chloride, polysorbate 80, benzyl alcohol, sodium acetate, and acetic acid). The solution is colorless to light yellow.
Trial: NCT04085276
Drug: JS001
RxNorm normalized name: Janus Kinase Inhibitor JS001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JS001 240mg, i.v., q3w; Other name: Toripalimab
Trial: NCT04085276
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, i.v., q3w;
Trial: NCT04170543
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02586623
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00428948
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was supplied as tablets.
Trial: NCT01926834
Drug: Erigeron Injection
RxNorm normalized name: ERIGERON CANADENSIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erigeron Injection, 30ml, iv, qd, for 7days
Trial: NCT01926834
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline, 500ml,i.v.,qd, for 7 days
Trial: NCT02975349
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo were administered for 24 weeks
Trial: NCT00004266
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02315417
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03254199
Drug: Placebo ODT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ODT taken three times daily for 28 days
Trial: NCT00854880
Drug: PDC339
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00854880
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00556894
Drug: CF101
RxNorm normalized name: CF101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally q12h
Trial: NCT00556894
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally q12h
Trial: NCT04393493
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One 50 mg pill administrated every 24 hours in group B
Trial: NCT00108836
Drug: XBD173
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02982642
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be assigned placebo identified to 1612 capsule,3 capsules per time, 3 times per day
Trial: NCT04173403
Drug: 450mg AK102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AK102 Q4W
Trial: NCT04173403
Drug: 150mg AK102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AK102 Q2W
Trial: NCT00102063
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet po qd x 42 days
Trial: NCT02337569
Drug: NPC-02
RxNorm normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02337569
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03393377
Drug: fluvastatin 10 mg and valsartan 20 mg
RxNorm normalized name: fluvastatin 20 MG
DrugBank: Fluvastatin (DB01095)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00756730
Drug: ATV/r
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switch to ATV/r at a dose of 300mg/100mg QD for 24 weeks. Subjects will continue to maintain their background NRTI drugs throughout the screening period and during the entire study.
Trial: NCT00756730
Drug: DRV/r
FDA approved: no
EMA approved: no
PMDA approved: no
Description: We designed a study to determine if switching virologically suppressed patients on a regimen containing LPV/r or FPV/r to either DRV/r or ATV/r would result in improved TGs while maintaining virological suppression. Switch to DRV/r at a dose 800mg/100mg QD for 24 weeks. Subjects will continue to maintain their background NRTI drugs throughout the screening period and during the entire study.
Trial: NCT00149838
Drug: Antidepressant Regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Particpants who acheive remission with rTMS may start antidepressant medication in phase III.
Trial: NCT04417361
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be supplied in preloaded syringes, each with a dose of 120 mg. Participants will first receive the first month's supply (240 mg) at study visit 2, and then will receive a two month supply at study visit 3. So, at study visit 2 and 3, each participant will get two pre-filled syringes.
Trial: NCT01125800
Drug: LDE225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDE225/sonidegib capsules were supplied to the Investigators at dose strengths of 50 mg, 100 mg, 200 mg, and 250 mg.
Trial: NCT01688089
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01688089
Drug: Levodopa/carbidopa
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00177216
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo capsule was given with instructions to take it every night by mouth, 30 minutes prior to bedtime.
Trial: NCT01315314
Drug: Balance, Fresenius Medical Care, Germany
FDA approved: no
EMA approved: no
PMDA approved: no
Description: low glucose degradation product (GDP)-containing peritoneal dialysis fluid (PDF)
Trial: NCT04042545
Drug: PPP001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 cannabis dosing capsule inhaled 3 times a day with a vaporizer device
Trial: NCT04042545
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 placebo dosing capsule inhaled 3 times a day with a vaporizer device
Trial: NCT03383146
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injected subcutaneously twice daily.
Trial: NCT01862536
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily use in double blind study.
Trial: NCT03601910
Drug: D308 10mg Tab.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D308 10mg Tab.1T single oral administration under fasting condition
Trial: NCT03601910
Drug: CKD-380 10mg Tab.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CKD-380(Dapagliflozin) 10mg Tab.1T single oral administration under fasting condition
Trial: NCT00967512
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution for injection, intravenous infusion, 0.1 mg/kg/h x 24h x 4 days, and 0.4 mg/kg/h x 3h x 4 days
Trial: NCT01846689
Drug: ESS (medical food/drug)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription medical food erythropoietin stimulating system